X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Why Congress should prioritize fixing the 340B program

By Nicole Longo  |    March 2, 2023
Nearly all Americans nationwide agree: Lowering out-of-pocket costs for health care should be a top priority for policymakers. Luckily, there are commonsense policies Congress could implement to...   Read More

What they are saying: Nonprofit hospitals are gaming the system at the expense of patients

By Gabby Migliara  |    February 21, 2023
There have been some alarming stories uncovered by the media on ways nonprofit hospitals — many of which participate in the 340B drug pricing program — are taking advantage of the system and their...   Read More

340B program continues to drive shift in care to more expensive hospital settings

By Nicole Longo  |    December 15, 2022
Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group...   Read More

New analysis confirms hospitals markup prices for oncology therapies

By Gabby Migliara  |    April 21, 2022
A recent study from The Journal of the American Medical Association (JAMA) examined 61 hospitals using data made public under new requirements from a recent price transparency regulation. The...   Read More

340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients

By Nicole Longo  |    February 8, 2022
The 340B program was created 30 years ago to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers. The aim was...   Read More

New report: To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and the health system

By Gabby Migliara  |    October 14, 2021
A new study from the Employee Benefit Research Institute (EBRI) compared the difference in price for 72 physician-administered outpatient medicines – representing 73% of medicine spending – depending...   Read More

340B hospitals among those that provide lowest levels of community benefit across the country

By Nicole Longo  |    July 27, 2021
The 340B program reached $38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014....   Read More

Getting the 340B program back on track in 2021

By Nicole Longo  |    March 10, 2021
As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have been...   Read More

Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients

By Nicole Longo  |    December 17, 2020
The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the...   Read More

340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients

By Nicole Longo  |    October 23, 2020
The 340B program – a safety-net federal drug program meant to help vulnerable Americans – has become dominated by many large hospitals and for-profit corporations with no clear evidence they are...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."